NASDAQ:MYOSMYOS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MYOS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.88 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.89Now: $0.89▼$0.9250-Day Range$0.89MA: $1.03▼$1.1652-Week Range$0.74Now: $0.89▼$1.80Volume105,026 shsAverage Volume1.27 million shsMarket Capitalization$9.76 millionP/E RatioN/ADividend YieldN/ABeta1.04 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for MYOS. Previous Next 2.6 Community Rank Outperform VotesMYOS has received 109 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMYOS has received 102 “underperform” votes. (Add your “underperform” vote.)Community SentimentMYOS has received 51.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote “Outperform” if you believe MYOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMYOS does not currently pay a dividend.Dividend GrowthMYOS does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MYOS insiders have not sold or bought any company stock.Percentage Held by Insiders45.30% of the stock of MYOS is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.16% of the stock of MYOS is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MYOS are expected to grow in the coming year, from ($0.51) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MYOS is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MYOS is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMYOS has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MYOS Previous Symbol CUSIPN/A CIK1402479 Webwww.myosrens.com Phone973-509-0444Debt Debt-to-Equity Ratio0.06 Current Ratio2.89 Quick Ratio1.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.03 million Price / Sales9.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book3.69Profitability EPS (Most Recent Fiscal Year)($0.46) Net Income$-4,260,000.00 Net Margins-353.71% Return on Equity-176.31% Return on Assets-112.74%Miscellaneous Employees12 Outstanding Shares11,030,000Market Cap$9.76 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:MYOS Rates by TradingView Receive MYOS News and Ratings via Email Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter. MYOS (NASDAQ:MYOS) Frequently Asked Questions How has MYOS's stock been impacted by COVID-19 (Coronavirus)? MYOS's stock was trading at $0.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYOS stock has decreased by 9.7% and is now trading at $0.8850. View which stocks have been most impacted by Coronavirus. When is MYOS's next earnings date? MYOS is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for MYOS. How were MYOS's earnings last quarter? MYOS Co. (NASDAQ:MYOS) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.29 million for the quarter. MYOS had a negative return on equity of 176.31% and a negative net margin of 353.71%. View MYOS's earnings history. Has MYOS been receiving favorable news coverage? News headlines about MYOS stock have been trending somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MYOS earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMYOS. Are investors shorting MYOS? MYOS saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 51,400 shares, a decline of 22.4% from the April 15th total of 66,200 shares. Based on an average daily trading volume, of 41,400 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.0% of the shares of the company are short sold. View MYOS's Current Options Chain. Who are some of MYOS's key competitors? Some companies that are related to MYOS include Hoth Therapeutics (HOTH), RegeneRx Biopharmaceuticals (RGRX), Bellicum Pharmaceuticals (BLCM), Zafgen (ZFGN), Adamis Pharmaceuticals (ADMP), Neos Therapeutics (NEOS), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP), Citius Pharmaceuticals (CTXR), Akari Therapeutics (AKTX), Mereo BioPharma Group (MREO), Acer Therapeutics (ACER), Annovis Bio (ANVS), Neurotrope (NTRP) and Tocagen (TOCA). View all competitors. What other stocks do shareholders of MYOS own? Based on aggregate information from My MarketBeat watchlists, some companies that other MYOS investors own include Chesapeake Energy (CHK), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Biocept (BIOC), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO) and Ritter Pharmaceuticals (RTTR). Who are MYOS's key executives? MYOS's management team includes the following people: Mr. Joseph Mannello, CEO & Director (Age 61)Mr. Ren Ren, Global Chairman (Age 57)Mr. Joseph DiPietro, ControllerMr. Magshoud Dariani, Chief Technology OfficerMr. Kris Ohrenick, Head of Marketing What is MYOS's stock symbol? MYOS trades on the NASDAQ under the ticker symbol "MYOS." How do I buy shares of MYOS? Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MYOS's stock price today? One share of MYOS stock can currently be purchased for approximately $0.89. How big of a company is MYOS? MYOS has a market capitalization of $9.76 million and generates $1.03 million in revenue each year. The company earns $-4,260,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. MYOS employs 12 workers across the globe. What is MYOS's official website? The official website for MYOS is www.myosrens.com. How can I contact MYOS? MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
